Viewpoint Molecular Targeting, Inc.

Viewpoint scientists do it again! Viewpoint is excited to announce two additional grant approvals of $2M each for research in Pb isotope alpha particle therapy for neuroblastoma and metastatic melanoma. https://lnkd.in/g8JrCHqQ SBIR Phase II Grants bring the cumulative grant total to approximately $17 million from the National Institutes of Health and National Cancer Institute CORALVILLE, IA / October 11, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced the award of two additional Small Business Innovation Research (SBIR) phase II grants totaling $4 million. The first award of $2 million is intended to assess image-guided dosimetry-based alpha particle therapy for neuroblastoma. The second award of $2 million was awarded for the purpose of combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic melanoma. These recently awarded grants bring the total amount of SBIR awards of approximately $17 million through October 2022 from the National Institutes of Health (NIH) and National Cancer Institute (NCI) to our principal collaborators at the University of Iowa, including Michael K. Schultz, Ph.D., our co-founder and Chief Scientific Officer, and Frances L. Johnson, MD, our co-founder, and Chief Operating Officer. “We are grateful that our science has been recognized since the Company’s inception with such significant support from the NIH and NCI to support our targeted alpha therapy development activities,” said Thijs Spoor, CEO of Viewpoint Molecular Targeting. Dr. Schultz commented, “as our researchers continue to expand the potential applications of targeted alpha therapies generally, and the compelling science behind Pb-212 specifically, we continue to be excited by the transformational nature we think our emerging discoveries will have on the lives of cancer patients.”   The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trials and commercial operations. For more information, please visit the Company’s website www.viewpointmt.com. #innovation #oncology #SBIR #melanoma #neuroblastoma #theranostics #Pb212 #alphatherapy